Contents:

1 Executive Summary 2 About Cancer Highlights™ 2.1 Cancer Focus Areas 2.2 Subscribe Today and Start Saving 2.2.1 Type of License 2.3 BioSeeker Group’s Oncology Team 3 Methodology 3.1 Cancer Highlights’™ Five Pillar Assessment 4 Table of Contents 4.1 List of Figures 4.2 List of Tables 5 Introduction 5.1 The Scope of this Report 5.2 Definitions 5.3 Abbreviations 6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment 6.1 Drug Repositioning in Oncology 6.2 Introduction to Prostate Cancer Therapeutic Targets in Oncology 6.2.1 Acid Phosphatase Activity Targets 6.2.2 Calcium Ion Binding Targets 6.2.3 Carboxy-lyase Activity Targets 6.2.4 Carboxypeptidase Activity Targets 6.2.5 Catalytic Activity Targets 6.2.6 Cell Adhesion Molecule Activity Targets 6.2.7 Chaperone Activity Targets 6.2.8 Chemokine Activity Targets 6.2.9 Complement Activity Targets 6.2.10 Cysteine-type Peptidase Activity Targets 6.2.11 Cytokine Activity Targets 6.2.12 DNA Binding Targets 6.2.13 DNA Repair Protein Targets 6.2.14 DNA Topoisomerase Activity Targets 6.2.15 DNA-directed DNA Polymerase Activity Targets 6.2.16 Extracellular Ligand-gated Ion Channel Activity Targets 6.2.17 G-protein Coupled Receptor Activity Targets 6.2.18 Growth Factor Activity Targets 6.2.19 GTPase Activator Activity Targets 6.2.20 Hormone Activity Targets 6.2.21 Hydrolase Activity Targets 6.2.22 Ion Channel Activity Targets 6.2.23 Isomerase Activity Targets 6.2.24 Kinase Activity Targets 6.2.25 Kinase Regulator Activity Targets 6.2.26 Ligand-dependent Nuclear Receptor Activity Targets 6.2.27 Ligase Activity Targets 6.2.28 Lipid Kinase Activity Targets 6.2.29 Lipid Phosphatase Activity Targets 6.2.30 Metallopeptidase Activity Targets 6.2.31 MHC Class I Receptor Activity Targets 6.2.32 Motor Activity Targets 6.2.33 Oxidoreductase Activity Targets 6.2.34 Peptidase Activity Targets 6.2.35 Peptide Hormone Targets 6.2.36 Peroxidase Activity Targets 6.2.37 Phosphoric Diester Hydrolase Activity Targets 6.2.38 Protein Binding Targets 6.2.39 Protein Serine/Threonine Kinase Activity Targets 6.2.40 Protein Serine/Threonine kinase activity Targets 6.2.41 Protein-tyrosine Kinase Activity Targets 6.2.42 Receptor Activity Targets 6.2.43 Receptor Binding Targets 6.2.44 Receptor Signaling Complex Scaffold Activity Targets 6.2.45 Receptor Signaling Protein Serine/Threonine Kinase Activity Targets 6.2.46 RNA Binding Targets 6.2.47 RNA-directed DNA Polymerase Activity Targets 6.2.48 Serine-type Peptidase Activity Targets 6.2.49 Structural Constituent of Cytoskeleton Targets 6.2.50 Superoxide Dismutase Activity Targets 6.2.51 Transcription Factor Activity Targets 6.2.52 Transcription Regulator Activity Targets 6.2.53 Translation Regulator Activity Targets 6.2.54 Transmembrane Receptor Activity Targets 6.2.55 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets 6.2.56 Transporter Activity Targets 6.2.57 Ubiquitin-specific Protease Activity Targets 6.2.58 Voltage-gated Ion Channel Activity Targets 6.2.59 Other Targets 6.3 The Cancer Genome Project and Prostate Cancer Therapeutic Targets 6.3.1 Prostate Cancer Therapeutic Targets Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer 6.4 Structure-based Drug Design in Prostate Cancer Therapeutics is Stimulated by Available Structure Data on Biological Targets 6.5 Target-Target Interactions among Identified Therapeutics Targets in Prostate Cancer 6.6 The Drug-Target Interactome 6.7 Protein Expression Levels of Identified Targets of Prostate Cancer Drugs 6.8 Pathway Assessment of Prostate Cancer Therapeutic Targets 6.8.1 Tools for Analysis of Cancer Pathways 6.8.2 Pathway Assessment 7 Emerging New Products to Established Ones: Drug Target Strategies by their Highest Stage of Development in the Prostate Cancer Pipeline 7.1 Terminated Drug Target Strategies of Prostate Cancer Drugs 7.2 Pre-registration to being Marketed: New and Unique Drug Target Strategies of Prostate Cancer Therapeutics 7.3 Phase III Clinical Development: New and Unique Drug Target Strategies of Prostate Cancer Therapeutics 7.4 Phase II Clinical Development: New and Unique Drug Target Strategies of Prostate Cancer Therapeutics 7.5 Phase I Clinical Development: New and Unique Drug Target Strategies of Prostate Cancer Therapeutics 7.6 Preclinical Development: New and Unique Drug Target Strategies of Prostate Cancer Therapeutics 7.7 No Development Data: New and Unique Drug Target Strategies of Prostate Cancer Therapeutics 7.8 Development Profiles of All Prostate Cancer Drugs in Oncology 7.9 The Competition Through Close Mechanistic Approximation of Prostate Cancer Therapeutics 8 Compound Strategies at Work: Competitive Benchmarking of Prostate Cancer Drugs by Compound Strategy 8.1 Small Molecules 8.1.1 Background 8.1.2 Target Strategies of Small Molecular Drugs 8.2 Peptide/Protein Drugs 8.2.1 Background 8.2.2 Target Strategies of Peptide and Protein Drugs 8.3 Antibodies and Antibody-like Structures 8.3.1 Background 8.3.2 Target Strategies of Antibody Drugs 8.4 Nucleic Acid Therapies 8.4.1 Background 8.4.2 Target Strategies of Nucleic Acid Drugs 8.5 Cell and Gene Therapy 8.5.1 Background 8.5.2 Target Strategies of Cell- and Gene Therapy Drugs 8.6 Drug Delivery and Nanotechnology 8.6.1 Background 8.6.2 Target Strategies of Reformulated Drugs 8.7 Compound Strategies based on Sub-Cellular Localization of Prostate Cancer Drug Targets 9 Pipeline and Portfolio Planning: Competitive Benchmarking of Prostate Cancer Cancer Therapeutic Pipeline by Investigator 9.1 Competitive Fall-Out Assessment 9.2 Changes in the Competitive Landscape: M&A, Bankruptcy and Name Change 9.3 Abbott 9.4 Abraxis BioScience 9.5 Active Biotech 9.6 Advantagene 9.7 AEgera 9.8 Aeterna Zentaris 9.9 Alchemia 9.10 Allos Therapeutics 9.11 AlphaVax 9.12 Alseres Pharmaceuticals 9.13 Altor BioScience 9.14 Ambrilia Biopharma 9.15 Amgen 9.16 Anavex Life Sciences 9.17 AndroBioSys 9.18 Antisense Pharma 9.19 Antisense Therapeutics 9.20 Antisoma 9.21 Aphios 9.22 ApopLogic Pharmaceuticals 9.23 Apotex 9.24 Apthera 9.25 Archer Biosciences 9.26 Ardana 9.27 Ariad 9.28 ArQule 9.29 Array BioPharma 9.30 Ascenta Therapeutics 9.31 Astellas 9.32 AstraZeneca 9.33 Attenuon 9.34 AVI BioPharma 9.35 Bavarian Nordic 9.36 Baxter International 9.37 Bayer 9.38 Bellicum Pharmaceuticals 9.39 Bioenvision 9.40 Biogen Idec 9.41 BioLineRx 9.42 BioNetWorks 9.43 Biostar 9.44 Boehringer Ingelheim 9.45 Bristol-Myers Squibb 9.46 BTG 9.47 Cadila 9.48 Camurus 9.49 Cancer Research Technology 9.50 Cel-Sci 9.51 Cell Genesys 9.52 Cell Therapeutics 9.53 Celldex Therapeutics 9.54 Celsion 9.55 Center of Molecular Immunology 9.56 Cephalon 9.57 ChemGenex Pharmaceuticals 9.58 Chemokine Therapeutics 9.59 Circadian Technologies 9.60 Cleveland BioLabs 9.61 Colby 9.62 Cylene Pharmaceuticals 9.63 Cytokinetics 9.64 Daiichi Sankyo 9.65 Debiopharm 9.66 Dendreon 9.67 Dongkook Pharm 9.68 ECI 9.69 Eisai 9.70 Elan 9.71 Eli Lilly 9.72 Endo Pharmaceuticals 9.73 Endocyte 9.74 Ensemble Discovery 9.75 EntreMed 9.76 EpiCept 9.77 EUSA Pharma 9.78 Exelixis 9.79 Ferring 9.80 Gemin X Biotechnologies 9.81 Generex 9.82 GENova Biotherapeutics 9.83 Genta 9.84 Genzyme 9.85 Gerolymatos 9.86 Geron 9.87 GlaxoSmithKline 9.88 Gloucester Pharmaceuticals 9.89 GlycoGenesys 9.90 Got-a-Gene 9.91 GP Pharm 9.92 Green Cross 9.93 GTx 9.94 Harbor BioSciences 9.95 Hoffmann-La Roche 9.96 Human Genome Sciences 9.97 Hybrigenics 9.98 Immunocore 9.99 ImmunoGen 9.100 Immunomedics 9.101 Incyte Corporation 9.102 Infinity Pharmaceuticals 9.103 Inovio 9.104 Insmed 9.105 Introgen Therapeutics 9.106 Ipsen 9.107 Isis Pharmaceuticals 9.108 Ivy Medical Chemicals 9.109 Johnson & Johnson 9.110 Karo Bio 9.111 Kyowa Hakko Kirin 9.112 LEAD Therapeutics 9.113 Ligand 9.114 Lorus Therapeutics 9.115 Mannkind 9.116 Marillion Pharmaceuticals 9.117 Med Discovery 9.118 Medarex 9.119 MediGene 9.120 MedImmune 9.121 Mediolanum 9.122 Medivation 9.123 Menarini 9.124 Merck & Co 9.125 Merck KGaA 9.126 Merrion Pharmaceuticals 9.127 MethylGene 9.128 Micromet 9.129 Mojave Therapeutics 9.130 Nektar Therapeutics 9.131 NeoPharm 9.132 Nerviano Medical Sciences 9.133 Nippon Shinyaku 9.134 Non-industrial Sources 9.135 Northwest Biotherapeutics 9.136 Norwood Abbey 9.137 Novacea 9.138 Novartis 9.139 Novogen 9.140 OncoGenex Pharmaceuticals 9.141 Oncothyreon 9.142 Oncovir 9.143 Orion Pharma 9.144 OSI Pharmaceuticals 9.145 Oxford BioMedica 9.146 Paladin Labs 9.147 Pantarhei Bioscience 9.148 Pepscan Therapeutics 9.149 Pfizer 9.150 Pharmacyclics 9.151 PharmaGap 9.152 PharmaMar 9.153 Pierre Fabre 9.154 Progen 9.155 Progenics Pharmaceuticals 9.156 ProNAi Therapeutics 9.157 ProStrakan 9.158 Protox Therapeutics 9.159 Q Chip 9.160 QLT 9.161 Receptor BioLogix 9.162 Regeneron 9.163 Regulon 9.164 Rexahn 9.165 Samyang 9.166 Sanofi-Aventis 9.167 Santaris Pharma 9.168 Sapphire Therapeutics 9.169 Semafore Pharmaceuticals 9.170 Serometrix 9.171 SGX Pharmaceuticals 9.172 Shire 9.173 Soligenix 9.174 SRI International 9.175 SuperGen 9.176 Supratek Pharma 9.177 Switch Pharma 9.178 Takeda 9.179 Tau Therapeutics 9.180 Thallion Pharmaceuticals 9.181 Therion Biologics 9.182 Titan Pharmaceuticals 9.183 Tokai Pharmaceuticals 9.184 TopoTarget 9.185 Transgene 9.186 Twinstrand Therapeutics 9.187 Unigene 9.188 United Biomedical 9.189 Vaxon Biotech 9.190 Velacor Therapeutics 9.191 Vion Pharmaceuticals 9.192 VioQuest 9.193 Viralytics 9.194 ViroTarg 9.195 VM Discovery 9.196 Wilex 9.197 Xerion 9.198 Xoma 9.199 YM BioSciences 10 Disclaimer 11 Drug Index 12 Company Index 4.1 List of Figures Figure 1: Visualization of Target-Target Interactions among Targets of Prostate Cancer Drugs Figure 2: The Drug-Target Interactions of Prostate Cancer Drugs - Large Clusters Figure 3: The Drug-Target Interactions of Prostate Cancer Drugs - Smaller Clusters Figure 4: Head-to-Head Targeting Interactions of Prostate Cancer Drugs – Larger Clusters Figure 5: Head-to-Head Targeting Interactions of Prostate Cancer Drugs – Smaller Clusters Figure 6: Primary Sub-cellular Localization of Drug Targets 4.2 List of Tables Table 1: Cancer Highlights’™ Five Pillar Assessment Table 2: Breakdown of the Included Prostate Cancer Pipeline by Stage of Development Table 3: Head to Head Target Competition among Prostate Cancer Drugs Table 4: Overview of Drug Target Strategy Themes Table 5: Terminally Ceased Therapeutic Prostate Cancer Targets Table 6: Drug Targets of Prostate Cancer Drugs Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census Table 7: Identity of Prostate Cancer Drug Targets with Available Biological Structures Table 8: Number of Target-Target Interactions among Targets of Prostate Cancer Drugs Table 9: Prostate Cancer Drug Targets with Available Protein Expression Profiles Table 10: Pathway Summary Table 11: Drug Targets without any Identified Assigned Pathways Table 12: Pathway Profiles According to BioCarta of Prostate Cancer Drug Targets Table 13: Pathway Profiles According to KEGG of Prostate Cancer Drug Targets Table 14: Pathway Profiles According to NetPath of Prostate Cancer Drug Targets Table 15: Number of Drug Target Strategies by their Highest Developmental Stage and Uniqueness Table 16: Top Competitive Target Strategies in Prostate Cancer Table 17: Terminated Drug Target Strategies of Prostate Cancer Drugs Table 18: New and Unique Target Strategies in Prostate Cancer Currently in Pre-registration to Marketed Table 19: The Competition Through Close Mechanistic Approximation Between Pre-registration to Marketed Drugs in Prostate Cancer Table 20: New and Unique Prostate Cancer Target Strategies in Phase III Clinical Development Table 21: The Competition Through Close Mechanistic Approximation Between Phase III Drugs in Prostate Cancer Table 22: New and Unique Prostate Cancer Target Strategies in Phase II Clinical Development Table 23: The Competition Through Close Mechanistic Approximation Between Phase II Drugs in Prostate Cancer Table 24 New and Unique Prostate Cancer Target Strategies in Phase I Clinical Development Table 25: The Competition Through Close Mechanistic Approximation Between Phase I Drugs in Prostate Cancer Table 26: New and Unique Prostate Cancer Target Strategies in Preclinical Development Table 27: The Competition Through Close Mechanistic Approximation Between Preclinical Drugs in Prostate Cancer Table 28: New and Unique Prostate Cancer Target Strategies in Unknown Developmental Stage Table 29: The Competition Through Close Mechanistic Approximation Between Drugs with No Developmental Data in Prostate Cancer Table 30: The Progression, Maturity and Competitive Comparison of Target Strategies in Prostate Cancer Drug Development Table 31: The Competition Through Close Mechanistic Approximation Among All Drugs in Prostate Cancer Table 32: Overview of Compound Strategy Competition Among Prostate Cancer Drugs Table 33: Overview of the Competitive Landscape of Small Molecule Prostate Cancer Drugs Table 34: The Competition Through Close Mechanistic Approximation between Small Molecule Drugs in Prostate Cancer Table 35: Competitive Comparison of Target Strategies of Small Molecule Drugs in Prostate Cancer Table 36: Overview of the Competitive Landscape of Peptide Based Drugs in Prostate Cancer Table 37: The Competition Through Close Mechanistic Approximation between Peptide Based Drugs in Prostate Cancer Table 38: Competitive Comparison of Target Strategies of Peptide Based Drugs in Prostate Cancer Table 39: Overview of the Competitive Landscape of Protein Based Drugs in Prostate Cancer Table 40: The Competition Through Close Mechanistic Approximation between Protein Based Drugs in Prostate Cancer Table 41: Competitive Comparison of Target Strategies of Protein Based Drugs in Prostate Cancer Table 42: Overview of the Competitive Landscape of Antibody Drugs in Prostate Cancer Table 43: The Competition Through Close Mechanistic Approximation between Antibody Drugs in Prostate Cancer Table 44: Competitive Comparison of Target Strategies of Antibody Drugs in Prostate Cancer Table 45: Overview of the Competitive Landscape of Nucleic Acid Therapy Drugs in Prostate Cancer Table 46: The Competition Through Close Mechanistic Approximation between Nucleic Acid Therapy Drugs in Prostate Cancer Table 47: Competitive Comparison of Target Strategies of Nucleic Acid Drugs in Prostate Cancer Table 48: Potential Forms of Cell Therapy Table 49: Vectors in Gene Therapy Table 50: Overview of the Competitive Landscape of Cell Therapy based Drugs in Prostate Cancer Table 51: The Competition Through Close Mechanistic Approximation between Cell Therapy Drugs in Prostate Cancer Table 52: Competitive Comparison of Target Strategies of Cell Therapy Based Drugs in Prostate Cancer Table 53: Overview of the Competitive Landscape of Gene Therapy based Drugs in Prostate Cancer Table 54: The Competition Through Close Mechanistic Approximation between Gene Therapy Drugs in Prostate Cancer Table 55: Competitive Comparison of Target Strategies of Gene Therapy Based Drugs in Prostate Cancer Table 56:Overview of the Competitive Landscape of Reformulated Drugs in Prostate Cancer Table 57: The Competition Through Close Mechanistic Approximation between Reformulated Drugs in Prostate Cancer Table 58: Competitive Comparison of Target Strategies of Reformulated Drugs in Prostate Cancer Table 59: Compound Strategies based on Sub-Cellular Localization of Prostate Cancer Drug Targets Table 60: Summary Table of Changes in the Competitive Landscape of Prostate Cancer Drug Development Table 61: Abbott's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 62: Abraxis BioScience's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 63: Active Biotech's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 64: Advantagene's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 65: AEgera's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 66: Aeterna Zentaris’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 67: Alchemia's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 68: Allos Therapeutics’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 69: AlphaVax's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 70: Alseres Pharmaceuticals’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 71: Altor BioScience's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 72: Ambrilia Biopharma's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 73: Amgen's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 74: Anavex Life Sciences’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 75: AndroBioSys’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 76: Antisense Pharma's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 77: Antisense Therapeutics’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 78: Antisoma's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 79: Aphios’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 80: ApopLogic Pharmaceuticals’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 81: Apotex's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 82: Apthera's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 83: Archer Biosciences’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 84: Ardana's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 85: Ariad's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 86: ArQule's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 87: Array BioPharma's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 88: Ascenta Therapeutics’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 89: Astellas’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 90: AstraZeneca's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 91: Attenuon's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 92: AVI BioPharma's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 93: Bavarian Nordic's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 94: Baxter International's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 95: Bayer's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 96: Bellicum Pharmaceuticals’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 97: Bioenvision's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 98: Biogen Idec's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 99: BioLineRx's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 100: BioNetWorks’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 101: Biostar's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 102: Boehringer Ingelheim's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 103: Bristol-Myers Squibb's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 104: BTG's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 105: Cadila's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 106: Camurus’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 107: Cancer Research Technology's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 108: Cel-Sci's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 109: Cell Genesys’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 110: Cell Therapeutics’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 111: Celldex Therapeutics’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 112: Celsion's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 113: Center of Molecular Immunology's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 114: Cephalon's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 115: ChemGenex Pharmaceuticals’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 116: Chemokine Therapeutics’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 117: Circadian Technologies’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 118: Cleveland BioLabs’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 119: Colby's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 120: Cylene Pharmaceuticals’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 121: Cytokinetics’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 122: Daiichi Sankyo's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 123: Debiopharm's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 124: Dendreon's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 125: Dongkook Pharm's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 126: ECI's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 127: Eisai's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 128: Elan's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 129: Eli Lilly's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 130: Endo Pharmaceuticals’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 131: Endocyte's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 132: Ensemble Discovery's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 133: EntreMed's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 134: EpiCept's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 135: EUSA Pharma's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 136: Exelixis’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 137: Ferring's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 138: Gemin X Biotechnologies’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 139: Generex's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 140: GENova Biotherapeutics’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 141: Genta's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 142: Genzyme's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 143: Gerolymatos’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 144: Geron's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 145: GlaxoSmithKline's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 146: Gloucester Pharmaceuticals’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 147: GlycoGenesys’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 148: Got-a-Gene's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 149: GP Pharm's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 150: Green Cross’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 151: GTx's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 152: Harbor BioSciences’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 153: Hoffmann-La Roche's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 154: Human Genome Sciences’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 155: Hybrigenics’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 156: Immunocore's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 157: ImmunoGen's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 158: Immunomedics’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 159: Incyte Corporation's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 160: Infinity Pharmaceuticals’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 161: Inovio's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 162: Insmed's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 163: Introgen Therapeutics’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 164: Ipsen's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 165: Isis Pharmaceuticals’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 166: Ivy Medical Chemicals’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 167: Johnson & Johnson's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 168: Karo Bio's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 169: Kyowa Hakko Kirin's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 170: LEAD Therapeutics’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 171: Ligand's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 172: Lorus Therapeutics’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 173: Mannkind's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 174: Marillion Pharmaceuticals’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 175: Med Discovery's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 176: Medarex's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 177: MediGene's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 178: MedImmune's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 179: Mediolanum's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 180: Medivation's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 181: Menarini's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 182: Merck & Co's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 183: Merck KGaA's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 184: Merrion Pharmaceuticals’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 185: MethylGene's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 186: Micromet's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 187: Mojave Therapeutics’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 188: Nektar Therapeutics’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 189: NeoPharm's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 190: Nerviano Medical Sciences’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 191: Nippon Shinyaku's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 192: Non-industrial source's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 193: Northwest Biotherapeutics’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 194: Norwood Abbey's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 195: Novacea's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 196: Novartis’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 197: Novogen's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 198: OncoGenex Pharmaceuticals’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 199: Oncothyreon's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 200: Oncovir's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 201: Orion Pharma's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 202: OSI Pharmaceuticals’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 203: Oxford BioMedica's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 204: Paladin Labs’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 205: Pantarhei Bioscience's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 206: Pepscan Therapeutics’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 207: Pfizer's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 208: Pharmacyclics’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 209: PharmaGap's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 210: PharmaMar's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 211: Pierre Fabre's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 212: Progen's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 213: Progenics Pharmaceuticals’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 214: ProNAi Therapeutics’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 215: ProStrakan's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 216: Protox Therapeutics’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 217: Q Chip's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 218: QLT's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 219: Receptor BioLogix's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 220: Regeneron's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 221: Regulon's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 222: Rexahn's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 223: Samyang's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 224: Sanofi-Aventis’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 225: Santaris Pharma's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 226: Sapphire Therapeutics’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 227: Semafore Pharmaceuticals’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 228: Serometrix's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 229: SGX Pharmaceuticals’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 230: Shire's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 231: Soligenix's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 232: SRI International's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 233: SuperGen's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 234: Supratek Pharma's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 235: Switch Pharma's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 236: Takeda's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 237: Tau Therapeutics’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 238: Thallion Pharmaceuticals’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 239: Therion Biologics’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 240: Titan Pharmaceuticals’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 241: Tokai Pharmaceuticals’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 242: TopoTarget's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 243: Transgene's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 244: Twinstrand Therapeutics’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 245: Unigene's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 246: United Biomedical's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 247: Vaxon Biotech's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 248: Velacor Therapeutics’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 249: Vion Pharmaceuticals’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 250: VioQuest's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 251: Viralytics’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 252: ViroTarg's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 253: VM Discovery's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 254: Wilex's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 255: Xerion's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 256: Xoma's Included Prostate Cancer Drug Pipeline and Competitive Fall-Out Table 257: YM BioSciences’ Included Prostate Cancer Drug Pipeline and Competitive Fall-Out

Companies Mentioned

- Abbott - Abraxis BioScience - Active Biotech - Advantagene - AEgera - Aeterna Zentaris - Alchemia - Allos Therapeutics - AlphaVax - Alseres Pharmaceuticals - Altor BioScience - Ambrilia Biopharma - Amgen - Anavex Life Sciences - AndroBioSys - Antisense Pharma - Antisense Therapeutics - Antisoma - Aphios - ApopLogic Pharmaceuticals - Apotex - Apthera - Archer Biosciences - Ardana - Ariad - ArQule - Array BioPharma - Ascenta Therapeutics - Astellas - AstraZeneca - Attenuon - AVI BioPharma - Bavarian Nordic - Baxter International - Bayer - Bellicum Pharmaceuticals - Bioenvision - Biogen Idec - BioLineRx - BioNetWorks - Biostar - Boehringer Ingelheim - Bristol-Myers Squibb - BTG - Cadila - Camurus - Cancer Research Technology - Cel-Sci - Cell Genesys - Cell Therapeutics - Celldex Therapeutics - Celsion - Center of Molecular Immunology - Cephalon - ChemGenex Pharmaceuticals - Chemokine Therapeutics - Circadian Technologies - Cleveland BioLabs - Colby - Cylene Pharmaceuticals - Cytokinetics - Daiichi Sankyo - Debiopharm - Dendreon - Dongkook Pharm - ECI - Eisai - Elan - Eli Lilly - Endo Pharmaceuticals - Endocyte - Ensemble Discovery - EntreMed - EpiCept - EUSA Pharma - Exelixis - Ferring - Gemin X Biotechnologies - Generex - GENova Biotherapeutics - Genta - Genzyme - Gerolymatos - Geron - GlaxoSmithKline - Gloucester Pharmaceuticals - GlycoGenesys - Got-a-Gene - GP Pharm - Green Cross - GTx - Harbor BioSciences - Hoffmann-La Roche - Human Genome Sciences - Hybrigenics - Immunocore - ImmunoGen - Immunomedics - Incyte Corporation - Infinity Pharmaceuticals - Inovio - Insmed - Introgen Therapeutics - Ipsen - Isis Pharmaceuticals - Ivy Medical Chemicals - Johnson & Johnson - Karo Bio - Kyowa Hakko Kirin - LEAD Therapeutics - Ligand - Lorus Therapeutics - Mannkind - Marillion Pharmaceuticals - Med Discovery - Medarex - MediGene - MedImmune - Mediolanum - Medivation - Menarini - Merck & Co - Merck KGaA - Merrion Pharmaceuticals - MethylGene - Micromet - Mojave Therapeutics - Nektar Therapeutics - NeoPharm - Nerviano Medical Sciences - Nippon Shinyaku - Non-industrial Sources - Northwest Biotherapeutics - Norwood Abbey - Novacea - Novartis - Novogen - OncoGenex Pharmaceuticals - Oncothyreon - Oncovir - Orion Pharma - OSI Pharmaceuticals - Oxford BioMedica - Paladin Labs - Pantarhei Bioscience - Pepscan Therapeutics - Pfizer - Pharmacyclics - PharmaGap - PharmaMar - Pierre Fabre - Progen - Progenics Pharmaceuticals - ProNAi Therapeutics - ProStrakan - Protox Therapeutics - Q Chip - QLT - Receptor BioLogix - Regeneron - Regulon - Rexahn - Samyang - Sanofi-Aventis - Santaris Pharma - Sapphire Therapeutics - Semafore Pharmaceuticals - Serometrix - SGX Pharmaceuticals - Shire - Soligenix - SRI International - SuperGen - Supratek Pharma - Switch Pharma - Takeda - Tau Therapeutics - Thallion Pharmaceuticals - Therion Biologics - Titan Pharmaceuticals - Tokai Pharmaceuticals - TopoTarget - Transgene - Twinstrand Therapeutics - Unigene - United Biomedical - Vaxon Biotech - Velacor Therapeutics - Vion Pharmaceuticals - VioQuest - Viralytics - ViroTarg - VM Discovery - Wilex - Xerion - Xoma - YM BioSciences